Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis

Garg, Amit; Lavian, Jonathan; Lin, Gloria; Strunk, Andrew; Alloo, Allireza

doi:10.1016/j.jaad.2017.02.005

Cited by 164 publications

(159 citation statements)

References 7 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…The incidence of HS disproportionally impacts adults 18 to 29 years of age [1]. Thus, HS onset and diagnosis occurs during the most potentially productive years of life [29• •].…”

Section: Hs and Disabilitymentioning

confidence: 99%

See 1 more Smart Citation

Pain, Psychological Comorbidities, Disability, and Impaired Qualify of Life in Hidradenitis Suppurativa

Patel

Hoffman

Buse

et al. 2017

Curr Pain Headache Rep

View full text Add to dashboard Cite

Purpose of Review Hidradenitis suppurativa (HS) is a chronic, painful dermatologic disease characterized by recurrent inflammatory nodules and abscesses of intertriginous areas such as the axilla and groin. People with HS suffer from greater pain and associated psychological comorbidities, including depression, anxiety, disability, and impairments in quality of life (QoL), compared to those with other dermatologic conditions. Our review focuses on the occurrence of pain and these relationships. Recent Findings The existing literature indicates that acute and chronic pain, depression, anxiety, and disability all contribute to poor quality of life in individuals with HS. Despite the central role of pain and distress in the presentation of HS, few studies have empirically evaluated the impact of pain and gaps remain in the existing psychosocial literature. There are no formal guidelines for treating HS-specific pain or psychological comorbidities. Summary The results of this review show a clear and pressing need to develop treatment recommendations and effective interventions for addressing acute and chronic pain, psychological comorbidities, disability, and impaired quality of life among people with HS. This review outlines a multidisciplinary approach to treating and managing pain and psychological comorbidities.

show abstract

“…The incidence of HS disproportionally impacts adults 18 to 29 years of age [1]. Thus, HS onset and diagnosis occurs during the most potentially productive years of life [29• •].…”

Section: Hs and Disabilitymentioning

confidence: 99%

“…The disease is often under-diagnosed and misdiagnosed, and typically results in a considerable delay to diagnosis [1, 2]. While pain is a central and debilitating feature of the disease, few studies have empirically evaluated pain associated with HS [3].…”

Section: Introductionmentioning

confidence: 99%

Pain, Psychological Comorbidities, Disability, and Impaired Qualify of Life in Hidradenitis Suppurativa

Patel

Hoffman

Buse

et al. 2017

Curr Pain Headache Rep

View full text Add to dashboard Cite

show abstract

“…A Danish trial did not report race for any participants [36]. Two trials did have cohorts containing 19–20% AA; however, this still contrasts with results from studies reporting that AA make up to 65% of patients with HS in the USA, have a 1-year incidence of HS more than double that of Caucasians, and have the highest 1-year incidence of HS across all age groups [4, 5, 34, 35]. Furthermore, none of the trials reported the percentage of patients that were Hispanic or stratified the responses to adalimumab by race.…”

Section: Treatment Response In Socmentioning

confidence: 99%

“…Although the prevalence of HS varies (from 0.00033 to 4.1%), studies have reported an increased prevalence in African and Hispanic populations, as well as in women [4, 5]. The disease burden of HS is largely due to a profound physical and psychological impact, which leads to depression and impaired quality of life (QoL) [6, 7].…”

Section: Introductionmentioning

confidence: 99%

Hidradenitis Suppurativa: Disease Burden and Etiology in Skin of Color

2017

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease. Although most studies on HS are conducted in largely Caucasian populations, evidence demonstrates a higher prevalence in patients with skin of color, including African and Hispanic populations. These racial subgroups are likely at risk for greater disease burden due to a higher prevalence of components of the metabolic syndrome, comorbid depression, and low socioeconomic status; however, there is a paucity of research in these populations. Additionally, studies examining the genetic and anatomical basis for HS, as well as the response to HS therapies, are lacking for patients with skin of color. Complicating this issue is the limited access to effective medical care, including dermatologists, for African and Hispanic populations as well as other minority groups. In this review, we identify gaps in the knowledge base, highlight the association between HS and patients with skin of color, and provide direction for much needed research into this condition.

show abstract

“…Hidradenitis suppurativa (HS) is a chronic, painful, and debilitating skin disease with an estimated prevalence of 0.1–4% worldwide [1, 2]. The primary lesions are inflammatory nodules that may develop into abscesses and sinus tracts with subsequent scarring, affecting flexural sites such as the axillae and groins [1, 3].…”

Section: Introductionmentioning

confidence: 99%

Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument

Thorlacius

Esmann

Miller

et al. 2019

Skin Appendage Disord

View full text Add to dashboard Cite

Background: Hidradenitis suppurativa (HS) is a chronic and painful skin disease. In addition, HS lesions may be associated with pus and odour, potentially leading to significant stigma and, consequently, greatly affected quality of life (QOL). QOL is a multidimensional construct, which can be measured in various ways. However, generic or dermatologic QOL measures may not capture changes in QOL particularly affected in HS. Accordingly, patients and experts included in the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC) agreed that future clinical HS trials should measure HS-specific QOL. Objectives: To develop an HS-specific QOL instrument (HiSQOL, Hidradenitis Suppurativa Quality of life). Method: The initial phases of the questionnaire development, described in this study, included item generation by patient interviews, development of a pilot questionnaire, questionnaire refinement, and pilot testing. Results: For item generation, 21 patients were interviewed individually or in focus groups. Analysis of the interviews identified 105 candidate items and, next, a pilot questionnaire was developed. Finally, item reduction and two rounds of pilot testing resulted in a 23-item questionnaire representing physical, psychological, and social QOL dimensions. Conclusions: We have comprehensively explored on HS’s possible effect on the QOL of the affected individuals and identified a 23-item HS-specific QOL questionnaire. The questionnaire proved to be feasible, acceptable, and comprehensible in the second round of pilot testing. With HiSQOL, researchers can measure HS-specific QOL in future clinical trials, potentially enabling them to discover more effective treatment options. It is envisaged, that after thorough validation in a trial setting, a streamlined version of HISQOL may also become available for clinical use in daily practice.

show abstract

Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis

Cited by 164 publications

References 7 publications

Pain, Psychological Comorbidities, Disability, and Impaired Qualify of Life in Hidradenitis Suppurativa

Pain, Psychological Comorbidities, Disability, and Impaired Qualify of Life in Hidradenitis Suppurativa

Hidradenitis Suppurativa: Disease Burden and Etiology in Skin of Color

Development of HiSQOL: A Hidradenitis Suppurativa-Specific Quality of Life Instrument

Contact Info

Product

Resources

About